Drug Trial Radar · NCT05080218
COVID-19 VaccinE Response in Rheumatology Patients
Last checked: Nov 20, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
841
Actual
Start
Nov 15, 2021
Primary completion
Apr 4, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Jeffrey CurtisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Alabama at Birmingham; University of Nebraska; University of Pennsylvania; AbbVie; Bristol-Myers Squibb; Novartis; Eli Lilly and Company; Pfizer; Illumination Health
- First posted
- Oct 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (\>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment. A primary objective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study.
Conditions
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Spondylarthritis
Interventions
UpadacitinibDrug
Hold UPA x 2 weeks at time of COVID booster
AbataceptDrug
Hold SQ ABA x 2 weeks at time of COVID booster
SecukinumabDrug
Hold SEC x 2 weeks at time of COVID booster
TofacitinibDrug
Hold TOF x 2 weeks at time of COVID booster
TNF InhibitorDrug
Hold SQ TNFi x 2 weeks at time of COVID booster
Canakinumab InjectionDrug
Hold CAN TNFi x 2 weeks at time of COVID booster
BaricitinibDrug
Hold BAR x 2 weeks at time of COVID booster
IxekizumabDrug
Hold IXE x 2 weeks at time of COVID booster
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantitative ratio post booster vs. pre-booster of IgG against SARS-CoV-2 using electrochemiluminescent (ECL) technology against the receptor binding domain (RBD) of spike protein, stratified by treatment armTime frame: 6 weeks following COVID-19 vaccine booster
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Illumination Health/Bendcare
Hoover, Alabama
Rheumatology Care Center
Hoover, Alabama
Arizona Arthritis & Rheumatology Research, PLLC
Phoenix, Arizona
Attune Health
Beverly Hills, California
University of Nebraska Medical Center
Omaha, Nebraska
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Metroplex Clinical Research Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.